Cencora Inc. Common Stock (COR)
Stock · NYSE · Health Care
$340.81as of 10/16/2026
Price chart
Active signals
COR Signal Track Record
How signals performed across all stocks →What COR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | +1.5% | 65% | September 18, 2026 |
| Bollinger Band Breakout | 30 | +2.4% | 63% | September 2, 2026 |
| Bollinger Band Breakdown | 16 | +0.1% | 50% | September 17, 2026 |
| 200-Day Moving Average TouchActive now | 15 | +3.8% | 67% | October 5, 2026 |
| Any 20-session window (baseline) | +2.4% | 63% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About COR
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical c…
- Sector
- Health Care
- Industry
- Other Pharmaceuticals
- Employees
- 47,000
- Website
- www.cencora.com/
Fundamentals
- 1-day range
- $339.31$345.43
- Market cap
- $63.23B
- P/E (trailing)
- 24.39
- P/E (forward)
- 17.24
- EPS (trailing)
- $13.45
- Dividend yield
- 1.01%
- Beta
- 0.59
- Avg. volume
- 1.31M
- Ex-dividend date
- August 14, 2026
- Dividend pay date
- August 31, 2026
How Cencora Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Nov 25, 2025 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Cencora Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CORCencora Inc. Common Stock$340.92▼ 0.14%Market cap $63.23BP/E 24.39$244.82$377.54
- CAHCardinal Health Inc. Common Stock$254.06▲ 0.14%Market cap $55.66BP/E 32.94$151.87$258.3
- MCKMcKesson Corporation Common Stock$1,005▲ 0.62%Market cap $104.74BP/E 25.30$723.68$999
- HLFHerbalife Ltd. Common Shares$14.6▲ 0.21%Market cap $1.19BP/E 9.24$7.56$20.4
- NUSNu Skin Enterprises Inc. Common Stock$5.14▼ 1.34%Market cap $251.98MP/E 4.30$4.45$11.67
- ZSTKZeroStack Corp. Common Stock$4▼ 5.21%Market cap $30.78MP/E —$1.32$20.45
- HKPDCellyan Biotechnology Co. Ltd Class A Ordinary Shares$0.11▲ 0.00%Market cap $16.93MP/E —$0.095$1.72
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| COR Cencora Inc. Common Stock | $63.23B | 24.39 | $340.92 | ▼ 0.14% | $244.82$377.54 |
| CAH Cardinal Health Inc. Common Stock | $55.66B | 32.94 | $254.06 | ▲ 0.14% | $151.87$258.3 |
| MCK McKesson Corporation Common Stock | $104.74B | 25.30 | $1,005 | ▲ 0.62% | $723.68$999 |
| HLF Herbalife Ltd. Common Shares | $1.19B | 9.24 | $14.6 | ▲ 0.21% | $7.56$20.4 |
| NUS Nu Skin Enterprises Inc. Common Stock | $251.98M | 4.30 | $5.14 | ▼ 1.34% | $4.45$11.67 |
| ZSTK ZeroStack Corp. Common Stock | $30.78M | — | $4 | ▼ 5.21% | $1.32$20.45 |
| HKPD Cellyan Biotechnology Co. Ltd Class A Ordinary Shares | $16.93M | — | $0.11 | ▲ 0.00% | $0.095$1.72 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- UBS Maintains Buy on Cencora, Lowers Price Target to $400benzinga · 10/16/2026
- If You Invested $1000 In Cencora Stock 10 Years Ago, You Would Have This Much TodayBenzinga · 10/8/2026
- Cencora Q3 2026 Earnings Call TranscriptBenzinga · 10/8/2026
- Leerink Partners Maintains Outperform on Cencora, Raises Price Target to $388Benzinga · 10/7/2026
- Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?Yahoo · 10/6/2026
- Cencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs GrowSeekingAlpha · 10/6/2026
- Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?Yahoo · 10/4/2026
- Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings ReleaseYahoo · 10/2/2026
- 2 Cash-Producing Stocks with Promising Prospects and 1 We Brush OffYahoo · 10/2/2026
Insider Activity
Insider Actions →- Lazarus Krikorian · October 1, 2026 · Sale986 @ $303.18
- Robert E. Sanchez · October 1, 2026 · Grant275
- Lon R. Greenberg · September 16, 2026 · Sale1.3K @ $321.3
- Lazarus Krikorian · September 1, 2026 · Sale985 @ $325.97
- Elizabeth S. Campbell · August 24, 2026 · Sale11.3K @ $324.12
- Dennis M. Nally · July 31, 2026 · Grant113 @ $311.34
- Ellen Cooper · July 31, 2026 · Grant97 @ $311.34
- Lauren M. Tyler · July 31, 2026 · Grant97 @ $311.34
- Silvana Battaglia · June 30, 2026 · Grant58 @ $240.53
- Elizabeth S. Campbell · June 30, 2026 · Grant50 @ $240.53
- Lauren M. Tyler · June 22, 2026 · Buy550 @ $270.23
- Dermot Mark Durcan · June 18, 2026 · Buy4.0K @ $274.19
- Dermot Mark Durcan · May 28, 2026 · Buy4.0K @ $266.26
- Lauren M. Tyler · May 1, 2026 · Grant99 @ $304
- Dennis M. Nally · May 1, 2026 · Grant116 @ $304
Institutional Ownership
March 31, 2026
- Total shares held
- 165.00M
- Total value held
- $45.92B
- Institutional holders
- 1413
- Unknown19.94M
- Unknown9.59M
- Unknown9.19M
- Unknown7.32M
- Unknown6.69M
- Unknown6.29M
- Unknown5.57M
- Unknown4.55M
- Unknown4.53M
- Unknown4.48M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cencora Valuation and AI Impact: Analysts Debate Growth Prospects
Recent analyses debate whether Cencora is undervalued or if its raised guidance is already priced in, as the stock trades near its 52-week high and average analyst target. Other reports suggest the company's distribution model could benefit more from AI disruption than certain telehealth competitors. The stock is also compared to major pharmaceutical companies like AbbVie and Eli Lilly as market participants assess the healthcare sector.
Cencora Valuation and AI Impact: Analysts Debate Growth Prospects. Recent analyses debate whether Cencora is undervalued or if its raised guidance is already priced in, as the stock trades near its 52-week high and average analyst target. Other reports suggest the company's distribution model could benefit more from AI disruption than certain telehealth competitors. The stock is also compared to major pharmaceutical companies like AbbVie and Eli Lilly as market participants assess the healthcare sector.